{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:11:17Z","timestamp":1789009877165,"version":"build-2803163510"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T00:00:00Z","timestamp":1646006400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thrombosisresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.thromres.2022.02.020","type":"journal-article","created":{"date-parts":[[2022,2,26]],"date-time":"2022-02-26T18:54:54Z","timestamp":1645901694000},"page":"72-80","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["The effect of Bruton's tyrosine kinase inhibitor ibrutinib on atherothrombus formation under stenotic flow conditions"],"prefix":"10.1016","volume":"212","author":[{"given":"M.F.A.","family":"Karel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.M.E.","family":"Tullemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"D'Italia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.P.","family":"Lemmens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.A.M.","family":"Claushuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.J.E.","family":"Kuijpers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.E.M.","family":"Cosemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.thromres.2022.02.020_bb0005","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1586\/17474086.2015.1061427","article-title":"Ibrutinib for the treatment of Waldenstr\u00f6m macroglobulinemia","volume":"8","author":"Chakraborty","year":"2015","journal-title":"Expert. Rev. Hematol."},{"issue":"8","key":"10.1016\/j.thromres.2022.02.020_bb0010","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1080\/13543784.2017.1349097","article-title":"Bruton\u2019s tyrosine kinase inhibitors in B-cell lymphoma: current experience and future perspectives","volume":"26","author":"Seiler","year":"2017","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"1","key":"10.1016\/j.thromres.2022.02.020_bb0015","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1080\/13543784.2018.1404027","article-title":"Bruton\u2019s tyrosine kinase inhibitors: first and second generation agents for patients with chronic lymphocytic leukemia (CLL)","volume":"27","author":"Thompson","year":"2018","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"2","key":"10.1016\/j.thromres.2022.02.020_bb0020","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s12272-019-01124-1","article-title":"Development of BTK inhibitors for the treatment of B-cell malignancies","volume":"42","author":"Kim","year":"2019","journal-title":"Arch. Pharm. Res."},{"key":"10.1016\/j.thromres.2022.02.020_bb0025","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.3389\/fimmu.2017.01454","article-title":"Bruton's tyrosine kinase: an emerging key player in innate immunity","volume":"8","author":"Weber","year":"2017","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.thromres.2022.02.020_bb0030","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/imm.13416","article-title":"The role of Bruton's tyrosine kinase in the immune system and disease","volume":"164","author":"McDonald","year":"2021","journal-title":"Immunology"},{"issue":"12","key":"10.1016\/j.thromres.2022.02.020_bb0035","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1182\/bloodadvances.2016001883","article-title":"Current understanding of bleeding with ibrutinib use: a systematic review and meta-analysis","volume":"1","author":"Caron","year":"2017","journal-title":"Blood Adv."},{"issue":"5","key":"10.1016\/j.thromres.2022.02.020_bb0040","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1111\/jth.13651","article-title":"Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies","volume":"15","author":"Shatzel","year":"2017","journal-title":"J. Thromb. Haemost."},{"issue":"1","key":"10.1016\/j.thromres.2022.02.020_bb0045","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1080\/09537104.2020.1849600","article-title":"Novel antiplatelet strategies targeting GPVI, CLEC-2 and tyrosine kinases","volume":"32","author":"Harbi","year":"2021","journal-title":"Platelets"},{"issue":"8","key":"10.1016\/j.thromres.2022.02.020_bb0050","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1055\/s-0039-1687877","article-title":"Btk inhibitors as first oral atherothrombosis-selective antiplatelet drugs","volume":"119","author":"Busygina","year":"2019","journal-title":"Thromb. Haemost."},{"issue":"24","key":"10.1016\/j.thromres.2022.02.020_bb0055","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1182\/blood-2017-09-808808","article-title":"Oral Bruton tyrosine kinase inhibitors selectively block atherosclerotic plaque\u2013triggered thrombus formation in humans","volume":"131","author":"Busygina","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.thromres.2022.02.020_bb0060","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1152\/physrev.00016.2011","article-title":"New fundamentals in hemostasis","volume":"93","author":"Versteeg","year":"2013","journal-title":"Physiol. Rev."},{"issue":"10","key":"10.1016\/j.thromres.2022.02.020_bb0065","doi-asserted-by":"crossref","first-page":"3684","DOI":"10.1182\/blood.V92.10.3684","article-title":"Shear-dependent rolling on von Willebrand factor of mammalian cells expressing the platelet glycoprotein Ib-IX-V complex","volume":"92","author":"Fredrickson","year":"1998","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.thromres.2022.02.020_bb0070","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0092-8674(00)80983-6","article-title":"Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor","volume":"84","author":"Savage","year":"1996","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.thromres.2022.02.020_bb0075","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1182\/blood-2004-11-4434","article-title":"GPVI and \u03b12\u03b21 play independent critical roles during platelet adhesion and aggregate formation to collagen under flow","volume":"106","author":"Sarratt","year":"2005","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.thromres.2022.02.020_bb0080","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1096\/fj.04-1940fje","article-title":"Adhesion of human and mouse platelets to collagen under shear: a unifying model","volume":"19","author":"Auger","year":"2005","journal-title":"FASEB J."},{"issue":"5","key":"10.1016\/j.thromres.2022.02.020_bb0085","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.3390\/cancers13051103","article-title":"Bleeding by Bruton tyrosine kinase-inhibitors: dependency on drug type and disease","volume":"13","author":"Hundelshausen von","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.thromres.2022.02.020_bb0090","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3324\/haematol.2019.218545","article-title":"Low-dose Btk inhibitors selectively block platelet activation by CLEC-2","volume":"106","author":"Nicolson","year":"2021","journal-title":"Haematologica"},{"issue":"20","key":"10.1016\/j.thromres.2022.02.020_bb0095","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0960-9822(98)70471-3","article-title":"A role for Bruton\u2019s tyrosine kinase (Btk) in platelet activation by collagen","volume":"8","author":"Quek","year":"1998","journal-title":"Curr. Biol."},{"issue":"12","key":"10.1016\/j.thromres.2022.02.020_bb0100","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1093\/emboj\/19.12.2793","article-title":"Phosphatidylinositol 3,4,5-trisphosphate regulates Ca2+ entry via Btk in platelets and megakaryocytes without increasing phospholipase C activity","volume":"19","author":"Pasquet","year":"2000","journal-title":"EMBO J."},{"issue":"16","key":"10.1016\/j.thromres.2022.02.020_bb0105","doi-asserted-by":"crossref","first-page":"3464","DOI":"10.1182\/blood-2009-05-222273","article-title":"CLEC-2 is an essential platelet-activating receptor in hemostasis and thrombosis","volume":"114","author":"May","year":"2009","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.thromres.2022.02.020_bb0110","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1016\/j.thromres.2012.01.003","article-title":"Podoplanin expression in advanced atherosclerotic lesions of human aortas","volume":"129","author":"Hatakeyama","year":"2012","journal-title":"Thromb. Res."},{"issue":"9","key":"10.1016\/j.thromres.2022.02.020_bb0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0139357","article-title":"Vascular smooth muscle cells stimulate platelets and facilitate thrombus formation through platelet CLEC-2: implications in atherothrombosis","volume":"10","author":"Inoue","year":"2015","journal-title":"PLoS One"},{"issue":"26","key":"10.1016\/j.thromres.2022.02.020_bb0120","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1182\/blood-2014-06-583294","article-title":"Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions","volume":"124","author":"Levade","year":"2014","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.thromres.2022.02.020_bb0125","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1182\/blood-2006-01-011817","article-title":"Bruton tyrosine kinase is essential for botrocetin\/VWF-induced signaling and GPIb-dependent thrombus formation in vivo","volume":"108","author":"Liu","year":"2006","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.thromres.2022.02.020_bb0130","doi-asserted-by":"crossref","first-page":"3592","DOI":"10.1182\/blood-2003-04-1142","article-title":"Tec regulates platelet activation by GPVI in the absence of Btk","volume":"102","author":"Atkinson","year":"2003","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.thromres.2022.02.020_bb0135","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1161\/ATVBAHA.115.306130","article-title":"Ibrutinib inhibits platelet integrin \u03b1IIb\u03b23 outside-in signaling and thrombus stability but not adhesion to collagen","volume":"35","author":"Bye","year":"2015","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"24","key":"10.1016\/j.thromres.2022.02.020_bb0140","doi-asserted-by":"crossref","first-page":"4298","DOI":"10.1182\/bloodadvances.2019000640","article-title":"Ibrutinib, but not zanubrutinib, induces platelet receptor shedding of GPIb-IX-V complex and integrin \u03b1IIb\u03b23 in mice and humans","volume":"3","author":"Dobie","year":"2019","journal-title":"Blood Adv."},{"issue":"1","key":"10.1016\/j.thromres.2022.02.020_bb0145","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.atherosclerosis.2004.12.037","article-title":"Contribution of platelet glycoprotein VI to the thrombogenic effect of collagens in fibrous atherosclerotic lesions","volume":"181","author":"Cosemans","year":"2005","journal-title":"Atherosclerosis"},{"issue":"8","key":"10.1016\/j.thromres.2022.02.020_bb0150","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1096\/fj.04-2748com","article-title":"Human atheromatous plaques stimulate thrombus formation by activating platelet glycoprotein VI","volume":"19","author":"Penz","year":"2005","journal-title":"FASEB J."},{"issue":"11","key":"10.1016\/j.thromres.2022.02.020_bb0155","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.jacc.2009.11.051","article-title":"A 2-step mechanism of arterial thrombus formation induced by human atherosclerotic plaques","volume":"55","author":"Reininger","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"issue":"4","key":"10.1016\/j.thromres.2022.02.020_bb0160","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1073\/pnas.1209905110","article-title":"Atherosclerotic geometries exacerbate pathological thrombus formation poststenosis in a von willebrand factor-dependent manner","volume":"110","author":"Westein","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.thromres.2022.02.020_bb0165","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1515\/bmc-2019-0022","article-title":"Mechanochemistry of von Willebrand factor","volume":"10","author":"Lancellotti","year":"2019","journal-title":"Biomol. Concepts"},{"issue":"4","key":"10.1016\/j.thromres.2022.02.020_bb0170","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.jvs.2014.12.050","article-title":"Role of high shear rate in thrombosis","volume":"61","author":"Casa","year":"2015","journal-title":"J. Vasc. Surg."},{"issue":"4","key":"10.1016\/j.thromres.2022.02.020_bb0175","doi-asserted-by":"crossref","first-page":"FSO30","DOI":"10.4155\/fso.15.28","article-title":"The impact of blood shear rate on arterial thrombus formation","volume":"1","author":"Sakariassen","year":"2015","journal-title":"Future Sci. OA"},{"key":"10.1016\/j.thromres.2022.02.020_bb0180","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/jha2.269","article-title":"Comparison of inhibitory effects of irreversible and reversible Btk inhibitors on platelet function","volume":"2","author":"Tullemans","year":"2021","journal-title":"EJHaem"},{"issue":"1","key":"10.1016\/j.thromres.2022.02.020_bb0185","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s12195-021-00713-9","article-title":"Characterization of atherosclerotic plaque coating for thrombosis microfluidics assays","volume":"15","author":"Karel","year":"2021","journal-title":"Cell. Mol. Bioeng."},{"issue":"3","key":"10.1016\/j.thromres.2022.02.020_bb0190","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3109\/09537104.2011.630848","article-title":"Measurement of whole blood thrombus formation using parallel-plate flow chambers - a practical guide","volume":"23","author":"Van Kruchten","year":"2012","journal-title":"Platelets"},{"issue":"5","key":"10.1016\/j.thromres.2022.02.020_bb0195","doi-asserted-by":"crossref","first-page":"267","DOI":"10.5551\/jat.10.267","article-title":"Atherosclerosis and extracellular matrix","volume":"10","author":"Katsuda","year":"2003","journal-title":"J. Atheroscler. Thromb."},{"issue":"88(5)","key":"10.1016\/j.thromres.2022.02.020_bb0200","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1182\/blood.V88.5.1525.1525","article-title":"Platelets and shear stress","volume":"1","author":"Kroll","year":"1996","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.thromres.2022.02.020_bb0205","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s00109-006-0101-1","article-title":"The impact of blood rheology on the molecular and cellular events underlying arterial thrombosis","volume":"84","author":"Nesbitt","year":"2006","journal-title":"J. Mol. Med."},{"issue":"11","key":"10.1016\/j.thromres.2022.02.020_bb0210","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1111\/j.1538-7836.2006.02177.x","article-title":"Biorheology subcommittee of the SSC of the ISTH. Flow-based assays for global assessment of hemostasis. Part 1: biorheologic considerations","volume":"4","author":"Zwaginga","year":"2006","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2022.02.020_bb0215","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.actbio.2018.04.002","article-title":"Effects of upstream shear forces on priming of platelets for downstream adhesion and activation","volume":"73","author":"Rahman","year":"2018","journal-title":"Acta Biomater."},{"key":"10.1016\/j.thromres.2022.02.020_bb0220","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.actbio.2019.04.028","article-title":"Downstream platelet adhesion and activation under highly elevated upstream shear forces","volume":"91","author":"Rahman","year":"2019","journal-title":"Acta Biomater."},{"key":"10.1016\/j.thromres.2022.02.020_bb0225","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s00277-020-04094-3","article-title":"Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes","volume":"100","author":"Archibald","year":"2021","journal-title":"Ann. Hematol."},{"issue":"15","key":"10.1016\/j.thromres.2022.02.020_bb0230","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1158\/1078-0432.CCR-19-2856","article-title":"Ibrutinib treatment for first-line and relapsed\/refractory chronic lymphocytic leukemia: final analysis of the pivotal phase Ib\/II PCYC-1102 study","volume":"26","author":"Byrd","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.thromres.2022.02.020_bb0235","doi-asserted-by":"crossref","first-page":"9977","DOI":"10.2147\/CMAR.S246385","article-title":"Mean platelet volume has prognostic value in chronic lymphocytic leukemia","volume":"12","author":"Masternak","year":"2020","journal-title":"Cancer Manag. Res."},{"issue":"4","key":"10.1016\/j.thromres.2022.02.020_bb0240","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1055\/s-2007-996108","article-title":"Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis","volume":"23","author":"Schr\u00f6r","year":"1997","journal-title":"Semin. Thromb. Hemost."},{"issue":"13","key":"10.1016\/j.thromres.2022.02.020_bb0245","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1182\/blood-2015-04-641654","article-title":"Fibrin activates GPVI in human and mouse platelets","volume":"126","author":"Alshehri","year":"2015","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.thromres.2022.02.020_bb0250","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1182\/blood-2015-02-629717","article-title":"Platelet glycoprotein VI binds to polymerized fibrin and promotes thrombin generation","volume":"126","author":"Mammadova-Bach","year":"2015","journal-title":"Blood"},{"issue":"06","key":"10.1016\/j.thromres.2022.02.020_bb0255","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1055\/s-0040-1710012","article-title":"Glycoprotein VI is not a functional platelet receptor for fibrin formed in plasma or blood","volume":"120","author":"Zhang","year":"2020","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2022.02.020_bb0260","author":"Takeda Pharmaceutical Company Limited"},{"issue":"1","key":"10.1016\/j.thromres.2022.02.020_bb0265","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1160\/TH04-12-0783","article-title":"Fibrillar type I collagens enhance platelet-dependent thrombin generation via glycoprotein VI with direct support of \u03b12\u03b21 but not \u03b1IIb\u03b23 integrin","volume":"94","author":"Lecut","year":"2005","journal-title":"Thromb. Haemost."}],"updated-by":[{"DOI":"10.1016\/j.thromres.2022.03.012","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000}}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384822000640?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384822000640?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:47:57Z","timestamp":1758736077000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384822000640"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":53,"alternative-id":["S0049384822000640"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2022.02.020","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effect of Bruton's tyrosine kinase inhibitor ibrutinib on atherothrombus formation under stenotic flow conditions","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2022.02.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}